Methods and compositions for treating hepatitis C virus
AssigneeIdenix Pharmaceuticals, Inc.
InventorsJean-Pierre Sommadossi, Paulo LaColla
Life of this patent
Estimating the term…
Abstract
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Claims27
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt or ester thereof.
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt or ester thereof.
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt or ester thereof.
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable thereof, optionally in a pharmaceutically acceptable carrier.
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.
A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D nucleoside compound of the structure:
- or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D-2′-C-branded pyrimidine nucleoside.
A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D-2′-C-branded pyrimidine nucleoside.
Dependencies are inferred from the claim text.